Ataraxis AI
PrivateLast Round
Early Funding
Apr 21, 2025
Est. Valuation
$68.4M
Total Funding Raised
$48.8M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Ataraxis AI operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was an Early Funding round in April 2025.
Ataraxis AI is a precision oncology company that develops AI-powered diagnostic tools to personalize cancer treatment selection and prognosis.
Sector
Healthcare & Life Sciences
Verticals
Medical AI, Medical Imaging, Precision Medicine, Healthcare Analytics
Business Model
B2B
Customer Profile
Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ataraxis AI Comparables
Compare Ataraxis AI with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PreciseDx | 84% | |
| ArteraAI | 84% | |
| Clairity, Inc. | 82% |
For institutional investors. Book with your work email.
Ataraxis AI Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Apr 21, 2025 | ||||
| Series A | Mar 5, 2025 | ||||
| Seed | Oct 31, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ataraxis AI Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bertelsmann Investments | Series A |
| Floating Point | Series A |
| Founders Fund | Series A |
| Floating Point Advisors | Series A |
| Thiel Bio | Series A |
| Obvious Ventures | Series A, Seed |
| AIX Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2026
Grew 20% QoQ, from 41 to 49 employees.
- Sep 1, 2026
Grew 18% QoQ, from 40 to 47 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesSep 18, 2026
Ataraxis launches generation of models.
- launchesSep 18, 2026
Ataraxis unveils models that predict treatment response and patient outcomes, initially focusing on breast cancer with broader testing across solid tumors, on Sep 19th '26.
For institutional investors. Book with your work email.
Ataraxis AI Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ataraxis AI's valuation, stock price, and market status.
Is Ataraxis AI a public or private company?
Ataraxis AI is a private company.
What is the current stock price of Ataraxis AI?
Ataraxis AI is a private company, so its shares have no public market price. Caplight tracks Ataraxis AI's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ataraxis AI worth (valuation)?
Ataraxis AI's valuation is estimated at $68.4M based on funding round data.
Can I buy Ataraxis AI stock?
Ataraxis AI shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ataraxis AI's last funding round?
Ataraxis AI's most recent funding round was Early Funding on April 21, 2025.
Who are the main investors in Ataraxis AI?
Key investors in Ataraxis AI include Obvious Ventures, AIX Ventures, Giant Ventures.
Will Ataraxis AI IPO soon?
No public IPO plans have been announced for Ataraxis AI.
How can I track Ataraxis AI secondary market activity?
Caplight tracks bids, offers, and trades in Ataraxis AI's shares on secondary markets.